219 related articles for article (PubMed ID: 25437144)
1. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
3. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
4. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
5. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
6. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
7. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
[TBL] [Abstract][Full Text] [Related]
8. The design, annotation, and application of a kinase-targeted library.
Xi H; Lunney EA
Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
[TBL] [Abstract][Full Text] [Related]
9. X-ray structural analysis of tau-tubulin kinase 1 and its interactions with small molecular inhibitors.
Xue Y; Wan PT; Hillertz P; Schweikart F; Zhao Y; Wissler L; Dekker N
ChemMedChem; 2013 Nov; 8(11):1846-54. PubMed ID: 24039150
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based design of kinase inhibitors: a practical guide.
Erickson JA
Methods Mol Biol; 2015; 1289():157-83. PubMed ID: 25709040
[TBL] [Abstract][Full Text] [Related]
11. De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
Urich R; Wishart G; Kiczun M; Richters A; Tidten-Luksch N; Rauh D; Sherborne B; Wyatt PG; Brenk R
ACS Chem Biol; 2013 May; 8(5):1044-52. PubMed ID: 23534475
[TBL] [Abstract][Full Text] [Related]
12. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of apo and inhibitor-bound TGFβR2 kinase domain: insights into TGFβR isoform selectivity.
Tebben AJ; Ruzanov M; Gao M; Xie D; Kiefer SE; Yan C; Newitt JA; Zhang L; Kim K; Lu H; Kopcho LM; Sheriff S
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):658-74. PubMed ID: 27139629
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
15. Pyrazolone based TGFbetaR1 kinase inhibitors.
Guckian K; Carter MB; Lin EY; Choi M; Sun L; Boriack-Sjodin PA; Chuaqui C; Lane B; Cheung K; Ling L; Lee WC
Bioorg Med Chem Lett; 2010 Jan; 20(1):326-9. PubMed ID: 19914068
[TBL] [Abstract][Full Text] [Related]
16. A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors.
Schulz MN; Fanghänel J; Schäfer M; Badock V; Briem H; Boemer U; Nguyen D; Husemann M; Hillig RC
Acta Crystallogr D Biol Crystallogr; 2011 Mar; 67(Pt 3):156-66. PubMed ID: 21358046
[TBL] [Abstract][Full Text] [Related]
17. Identification and further development of potent TBK1 inhibitors.
Richters A; Basu D; Engel J; Ercanoglu MS; Balke-Want H; Tesch R; Thomas RK; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):289-98. PubMed ID: 25540906
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
